THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM)
Strontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014–2015, a su...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Russo |
| יצא לאור: |
IMA PRESS LLC
2018-09-01
|
| סדרה: | Научно-практическая ревматология |
| נושאים: | |
| גישה מקוונת: | https://rsp.mediar-press.net/rsp/article/view/2587 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
